UTAA09 / PersonGen Biomedicine - LARVOL DELTA

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Oncology

Anke Bio's joint-stock company's CAR-T cell injection clinical trial application has been accepted [Google translation] (new.qq.com) - "Anke Bio...announced that recently, the clinical trial application for the CD19-targeting off-the-shelf universal chimeric antigen receptor (CAR)-T cell injection (R&D code: UTAA09 injection) based on Vδ1T cells developed by Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd., in which the company holds a stake, was accepted by the Drug Review Center of the National Medical Products Administration, with the acceptance number: CXSL2500075. This drug is the first universal off-the-shelf CAR-T cell product independently developed by Boshengji, mainly used to treat adult relapsed/refractory acute B-lymphocytic leukemia (B-ALL)....This is also the first spot universal UCAR-Vδ1T cell product in China that has been accepted by the CDE."

New trial • B Acute Lymphoblastic Leukemia

On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

New P1 trial • Fibrosis • Hematological Disorders • Hepatology • Immunology • Inflammatory Arthritis • Lupus • Myositis • Primary Biliary Cholangitis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Thrombocytopenia • Thrombocytopenic Purpura

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov) - P=N/A | N=10 | Not yet recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

New trial • Fibrosis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis

The "off-the-shelf "CD19-CAR-Vδ1T cells demonstrated an enhanced therapeutic effect on B-cell malignancy models (AACR 2024) - "UTAA09 shows potential as an off-the-shelf allogeneic cellular therapy for the treatment of B-cell malignancies and autoimmune diseases derived from B cells."

Hematological Malignancies • Oncology • IL17A • IL2

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov) - P=N/A | N=10 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Myositis • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

New P1 trial • Hematological Malignancies • Lymphoma • Oncology • IL6